Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01829997Not ApplicableCompleted

Assessment of nanOss Bioactive 3D in the Posterolateral Spine

Role: lead

NCT01832818Not ApplicableTerminated

Post-Market Study Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System

Role: lead

NCT02005341Not ApplicableWithdrawn

NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine

Role: lead

NCT01452516Not ApplicableTerminated

Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions

Role: lead

NCT01968993Not ApplicableCompleted

Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine

Role: lead

NCT00931515Not ApplicableCompleted

Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty

Role: lead

All 6 trials loaded